Angiographic restenosis after successful Wallstent stent implantation: an analysis of risk predictors.
ABSTRACT Follow-up angiographic study was performed in 86 patients after initially successful Wallstent stent (Medinvent, Lausanne, Switzerland) implantation between April 1986 and October 1990. The stent angiographic restenosis rate was 16% at a mean of 8 months after stenting despite the inclusion of a substantial number of patients at high risk of restenosis after percutaneous transluminal coronary angioplasty (PTCA). Of a total 15 variables analyzed, only suboptimal stent placement was found to be a significant predictor of stent restenosis. Age; gender; baseline New York Heart Association functional class; previous PTCA; indication for stenting; left ventricular ejection fraction; preangioplasty and immediate postangioplasty diameter stenosis severity; stented vessel site, lesional morphology; number, diameter, and length of stents implanted; and the interval between stenting and follow-up angiographic restudy were not significant risk factors of stent restenosis. Our study suggests that intracoronary stent implantation with the Wallstent may be a useful and promising adjunctive option after PTCA, particularly in patients at high risk of restenosis after PTCA. However, because of the significantly enhanced risk of restenosis after suboptimal stent implantation, we strongly recommend the selection and placement of Wallstent stents that adequately cover the entire length of the dilated coronary segment.
- [Show abstract] [Hide abstract]
ABSTRACT: This study assessed clinical and angiographic restenosis following the deployment of the long coronary Wallstent. Between May 1995 and June 1997, 182 Wallstents were deployed in 162 vessels in this unit. Forty-eight percent had an unstable coronary syndrome and 94% had AHA grade B or C lesions. The mean lesion length was 37 ± 20 mm and the mean stent length was 48 ± 20 mm. The procedural success rate was 99% and the primary success rate was 93%. Six in-patients suffered subacute stent thrombosis, the majority being in the era of anticoagulation rather than antiplatelet regimes. Seventy-three percent remained free of major adverse clinical events in the follow-up period, but 41% had angiographic restenosis. The Wallstent can be deployed in complex lesions with a high primary success rate and an acceptably low restenosis rate. The optimal management of in-stent restenosis remains to be defined. Cathet. Cardiovasc. Intervent. 48:287–293, 1999. © 1999 Wiley-Liss, Inc.Catheterization and Cardiovascular Interventions 10/1999; 48(3):287 - 293. · 2.51 Impact Factor
- Journal of Interventional Cardiology 09/1993; 6(3):241-269. · 1.50 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Percutaneous transluminal angioplasty, alone or in conjunction with thrombolysis and/or stenting, is now being performed in selected cases for hemodynamically significant stenosis (> 70%), involving both extracranial and intracranial cerebral vascular lesions. In the majority of cases, atherosclerosis was the major cause for symptomatic narrowing, although other causes included fibromuscular dysplasia, cerebral arteritis, postsurgical intimal hyperplasia, and acute arterial dissection. In some cases, direct intraarterial thrombolysis and angioplasty successfully restored perfusion to completely occluded blood vessels to the brain, and in other cases acute vessel closure or dissection of extracranial vessels was successfully managed with stent deployment. Since 1981, 325 patients, ranging in age from 9–78 years old, have been successfully treated by these techniques: 143 (44%) cases involved the anterior cerebral circulation; and 182 (56%) cases, the posterior cerebral circulation. Complications included 17 (5.2%) strokes (of which 4 [1.2%] died), and 23 (7.1%) cases of transient cerebral ischemia. Radiological follow-up demonstrated 24 (7.4%) cases of restenosis. This study indicates the feasibility of angioplasty as a treatment alternative, in conjunction with thrombolysis and intravascular stenting, for extracranial and intracranial obstructive cerebral vascular disorders and may also provide an interventional pathway in the treatment of acute stroke patients.Journal of Interventional Cardiology 06/2007; 9(3):245 - 255. · 1.50 Impact Factor